Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
National Research Corp Market Cap
From what 0 stock analysts predict, the share price for National Research Corp (NRC) might decrease by 100% in the next year. This is based on a 12-month average estimation for NRC. Price targets go from $ to $. The majority of stock analysts believe NRC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedNRC 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect National Research Corp to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NRC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of NRC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2018
Staff Count
435
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Michael D. Hays
Market Cap
$454.3M
In 2023, NRC generated $148.6M in revenue, which was a decrease of -1.97% from the previous year. This can be seen as a signal that NRC's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Zacks initiated coverage on NRC Health with a "Neutral" rating, citing AI innovations and partnerships, but also highlighting revenue declines, rising debt, and competition challenges.
Why It Matters - Zacks' "Neutral" rating indicates cautious sentiment on NRC Health, highlighting AI potential but also challenges like revenue drops and high debt, influencing investment decisions.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Signature Healthcare has partnered with NRC Health to improve its network using human-centered healthcare solutions and data-driven insights.
Why It Matters - Signature Healthcare's partnership with NRC Health signals potential growth in innovative healthcare solutions, likely improving service quality and operational efficiency, impacting investor confidence and stock performance.
Fri, 25 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - NRC Health (NASDAQ:NRC) reported Q3 2024 revenue of $35.8 million, down from $37.9 million year-over-year. Earnings per share decreased to $0.24 from $0.32 in Q3 2023.
Why It Matters - Declining revenue and earnings per share indicate potential challenges for NRC Health, affecting investor confidence and stock performance. Increased net indebtedness could further strain financial stability.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - NRC Health (NASDAQ:NRC) reported Q2 2024 revenue of $35M, down from $36M in Q2 2023. Earnings per share were $0.26, down from $0.29. Net indebtedness details were not disclosed.
Why It Matters - NRC Health's declining revenue and earnings per share indicate potential financial challenges, which could affect stock performance and investor sentiment.
Mon, 08 Jul 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - The health care sector has identified oversold stocks, indicating potential investment opportunities in undervalued companies.
Why It Matters - Oversold health care stocks indicate potential undervaluation, signaling a buying opportunity for investors seeking growth in a recovering sector.
Sat, 11 May 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - National Research Corporation will hold its Q1 2024 earnings conference call on May 8, 2024, at 11:00 AM ET, featuring key company executives.
Why It Matters - The Q1 2024 earnings call for National Research Corporation will provide insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
